Cutaneous Oncology and Management of Adverse Events

Following the success of the previous collection in this series, Cutaneous Oncology and Skin Cancer Genomics, we’re pleased to present a new collection across cutaneous oncology, onco-dermatology and related fields, to discuss “Cutaneous Oncology And Management Of Adverse Events”.

The relationship between oncological treatments and their dermatological side effects is an area of ongoing research. As cancer therapies advance, awareness and management of adverse events and skin toxicities must also develop, addressing patient quality of life and treatment adherence. Recent studies have shed light on novel manifestations of skin toxicities and underscored the importance of tailored management approaches. However, more research is needed to consolidate these findings and develop comprehensive management protocols.

This Research Topic aims to explore the management of cutaneous adverse events related to oncology treatments. We seek to gather insights into existing practices, novel management strategies, and future directions within cutaneous oncology. Specific areas include the differing presentations of adverse events and current management strategies, innovative techniques emerging from practitioners' experiences, and advancements impacting outcomes in cancer patients. Identifying reliable biomarkers and understanding the biology of cutaneous oncology and skin toxicities is also important to this field.

To gather further insights into adverse events and skin toxicities, we welcome articles addressing, but not limited to, the following themes:

• Cutaneous adverse events resulting from oncology treatments, ranging from common to uncommon and from mild to life-threatening reactions

• Current adverse event management practices and novel recommendations

• Skin manifestations following bone marrow transplant, such as Graft versus Host Disease

• Case reports or series exploring skin tumors, whether benign or malignant

• Clinical trials focusing on cutaneous oncology and adverse events

• Studies on complex cutaneous malignancies, examining biology, micro-environment, and serologic, genomic or histologic biomarkers with a view to therapeutic potential

We are open to considering manuscripts related to cutaneous oncology that may not address a point listed above, where this is pertinent to this research field. Article types welcomed include original research, case reports, clinical trials, brief research reports, reviews, and mini-reviews.


Topic Editor Jonathan Leventhal is a member of advisory boards for La Roche Posay, Sanofi, Regeneron, onQuality, and Azitra, and has received research funding from OnQuality and Azitra. All other Topic Editors declare no conflicts of interest.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Systematic Review

Keywords: cutaneous oncology, skin cancer, cutaneous malignancy, adverse events, skin toxicity, Graft versus Host Disease, tumor micro-environment, biomarkers, cancer drugs

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.